Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 43Recruiting 28Terminated 19Active not recruiting 13Unknown 7Withdrawn 4Not yet recruiting 3Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × abiraterone × Clear all
NCT06060587 2025-10-22

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

Northwestern University

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05705700 2023-02-27

Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03173859 2020-11-18

AERA

University of Athens

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡